Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2579491 | Thérapie | 2008 | 9 Pages |
Abstract
The use of anti-TNFα drugs has progressed over the last 4 years, in accordance with the “contrat de bon usage”. This is due to a better knowledge of these drugs, a good evolution of guidelines and the active participation of the medical team in the “contrat de bon usage” plan.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Christine Plard, Géraldine Serry, Pierre Faure, Isabelle Madelaine-Chambrin,